In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Aquestive Therapeutics Inc’s stock clocked out at $3.54, up 3.51% from its previous closing price of $3.42. In other words, the price has increased by $3.51 from its previous closing price. On the day, 2.72 million shares were traded.
Ratios:
To gain a deeper understanding of AQST’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.48 and its Current Ratio is at 4.87.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $17.
On May 10, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $8.Leerink Partners initiated its Outperform rating on May 10, 2024, with a $8 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 26 ’24 when Jung Cassie sold 44 shares for $4.87 per share. The transaction valued at 214 led to the insider holds 0 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 6.48.
Stock Price History:
Over the past 52 weeks, AQST has reached a high of $5.80, while it has fallen to a 52-week low of $2.12. The 50-Day Moving Average of the stock is 26.87%, while the 200-Day Moving Average is calculated to be -3.47%.
Shares Statistics:
A total of 99.32M shares are outstanding, with a floating share count of 91.68M. Insiders hold about 7.70% of the company’s shares, while institutions hold 42.63% stake in the company.
